In an 83‑year‑old patient with unresectable hepatocellular carcinoma (HCC) who is not a surgical candidate, how should the disease be staged and is anticoagulation of the portal vein indicated?

Staging and Anticoagulation in Unresectable HCC with Portal Vein Involvement

Staging Approach

Use the Barcelona Clinic Liver Cancer (BCLC) staging system, which classifies this patient as BCLC Stage C (advanced stage) due to portal vein involvement, regardless of tumor size or number. 1

Key Staging Components

The BCLC system integrates three critical prognostic domains that must all be assessed 1:

• Tumor burden: Number and size of nodules, presence of vascular invasion (portal vein thrombosis in this case), and extrahepatic spread 1
• Liver function: Child-Pugh class, bilirubin, albumin, presence of clinically relevant portal hypertension, and ascites 1
• Performance status: ECOG classification and presence of cancer-related symptoms 1

Required Staging Investigations

• Contrast-enhanced multiphasic CT or MRI to evaluate tumor extent, portal vein thrombosis classification (PV1-4), and extrahepatic spread 1
• Chest CT to assess for pulmonary metastases in advanced disease 1
• Child-Pugh scoring to determine liver functional reserve 1
• ECOG performance status assessment to guide treatment eligibility 1
• Serum AFP level, as values >400 ng/mL have prognostic significance and influence second-line treatment options 1

Portal Vein Thrombosis Classification

The extent of portal vein tumor thrombus (PVTT) must be classified 2, 3:

• PV1: Segmental branch involvement
• PV2: Secondary order branch involvement
• PV3: First-order branch involvement
• PV4: Main portal vein trunk or contralateral branch involvement

This classification directly affects prognosis and treatment selection, with PV3/PV4 involvement conferring worse outcomes and limiting surgical options. 2, 3

Anticoagulation for Portal Vein Tumor Thrombus

Therapeutic anticoagulation is NOT indicated for portal vein tumor thrombus in HCC. 1, 3

Critical Distinction: Tumor Thrombus vs. Bland Thrombus

Portal vein involvement in HCC represents tumor thrombus (PVTT), not bland venous thromboembolism 3. The management differs fundamentally:

• Tumor thrombus is a direct extension of viable HCC into the portal venous system and requires oncologic treatment, not anticoagulation 3
• Bland thrombus (non-malignant) would require anticoagulation per standard VTE protocols 1

Why Anticoagulation Is Contraindicated

• Portal hypertension and varices are common in cirrhotic patients with HCC, creating high bleeding risk 1, 4
• Anticoagulation does not treat tumor thrombus and provides no oncologic benefit 3
• Systemic therapy targeting the tumor is the appropriate treatment for PVTT 4, 2, 3

When to Consider Anticoagulation

The NCCN guidelines address anticoagulation only for bland splanchnic vein thrombosis (portal, mesenteric, splenic, or hepatic vein thrombosis without tumor involvement) 1:

• Acute bland portal vein thrombosis (<8 weeks, no collaterals): Consider anticoagulation if no contraindications exist 1
• Chronic bland portal vein thrombosis (>8 weeks): Risks and benefits of anticoagulation must be carefully weighed 1

In this 83-year-old patient with HCC and portal vein tumor thrombus, anticoagulation is not indicated and would increase bleeding risk without therapeutic benefit. 1, 3

Treatment Implications of BCLC Stage C

First-Line Systemic Therapy Options

For patients with Child-Pugh A liver function and ECOG performance status 0-1, atezolizumab plus bevacizumab is the preferred first-line treatment, with median overall survival of 19.2 months versus 13.4 months with sorafenib. 1, 4

Mandatory Pre-Treatment Assessment for Bevacizumab

• Endoscopic screening for esophageal varices must be performed within 6 months before initiating bevacizumab-containing regimens 1, 4
• Variceal prophylaxis (band ligation or β-blockers) must be completed before the first cycle if varices are present 4
• Gastrointestinal bleeding occurred in 7% of atezolizumab-bevacizumab patients versus 4.5% with sorafenib, even with mandatory variceal screening 1

Alternative First-Line Options

• Durvalumab plus tremelimumab (single dose of tremelimumab 75 mg IV, then durvalumab 1500 mg IV every 4 weeks) for patients who cannot receive bevacizumab due to untreated varices or high bleeding risk, with median OS of 16.4 months 4, 2
• Lenvatinib (8 mg daily for <60 kg or 12 mg daily for ≥60 kg) if immunotherapy is contraindicated, though lenvatinib has not been studied in patients with main portal vein invasion (PV4) and may not be appropriate for this population 1, 4
• Sorafenib 400 mg orally twice daily remains an alternative when other options are unsuitable 1

Patients Ineligible for Systemic Therapy

Systemic therapy should NOT be offered to patients with ECOG performance status ≥2 or Child-Pugh B8-9/C cirrhosis; these patients should receive palliative care only. 4

Common Pitfalls to Avoid

• Do not anticoagulate portal vein tumor thrombus—it is tumor extension, not bland thrombosis 1, 3
• Do not start atezolizumab-bevacizumab without recent endoscopic variceal assessment and treatment 1, 4
• Do not use lenvatinib in patients with main portal vein (PV4) involvement, as this population was excluded from the REFLECT trial 1
• Do not offer systemic therapy to patients with ECOG ≥2 or decompensated cirrhosis, as they derive no survival benefit and experience increased toxicity 4
• Do not rely solely on TNM staging for HCC, as it does not capture liver function or performance status and has limited prognostic value in advanced disease 1